Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Muriel Aline Spahn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium. Hauptthemen laut MEDLINE: Receptors, CXCR4, Indium Radioisotopes, Single-Domain Antibodies, Tomography, Emission-Computed, Single-Photon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: KU Leuven, H2020 Marie Sklodowska-Curie Actions, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in a range of pathologies, including cancers like multiple myeloma and non-Hodgkin lymphoma, inflammatory diseases such as rheumatoid arthritis, and viral infections like HIV. Currently, the most advanced radiotracer for CXCR4 imaging in clinics is [ 68 Ga]PentixaFor. However, its structure is prone to modifications, complicating the development of a specific CXCR4 fluorine-18-labeled tracer with good pharmacokinetic properties. This study aimed to screen multiple CXCR4-targeting variable domains of heavy-chain-only antibody (VHH or single-domain antibody (sdAb)) constructs to identify the most promising sdAb as a vector molecule for the future development of a CXCR4 fluorine-18 tracer. We have generated five CXCR4-specific sdAb constructs with a cysteine-containing C-terminal tag (C-Direct tag) (VUN400-C-Direct, VUN401-C-Direct, VUN410-C-Direct, VUN411-C-Direct, and VUN415-C-Direct) and one probe (VUN400-C) without. The reduced sdAbs were coupled to maleimide-DOTAGA for 111 In-labeling. Their binding affinity against human CXCR4 (hCXCR4) was assessed by using a previously described BRET-based displacement assay. The in vivo profile was assessed using naive mice. Based on the plasma stability (60 min post injection (p.i.)), we selected VUN400-C-Direct and its derivative VUN400-C for further evaluation. These compounds ([ 111 In]In-DOTAGA-VUN400-C-Direct and [ 111 In]In-DOTAGA-VUN400-C) were tested in mice bearing xenografts derived from U87.CD4, U87.CXCR4, and U87.CD4.CXCR4 cells through ex vivo biodistribution studies and SPECT/CT imaging. The six sdAb constructs were labeled with a high radiochemical conversion (75–97%) and purity (>95%). In radioactive binding assays using U87.CD4.CXCR4 cells, [ 111 In]In-DOTAGA-VUN400-C-Direct and [ 111 In]In-DOTAGA-VUN401-C-Direct displayed the highest cellular uptake, achieving 10.4 ± 1.6% and 11.5 ± 1.1%, respectively. In naive mice, [ 111 In]In-DOTAGA-VUN400-C-Direct showed the most favorable biodistribution profile, with low uptake across all organs except the kidneys (Standardized Uptake Value (SUV) > 50, n = 3, 60 min p.i.), but average plasma stability (40.6 ± 9.4%, n = 3, 60 min p.i.). In a xenografted tumor model, [ 111 In]In-DOTAGA-VUN400-C-Direct showed only minor uptake (SUV U87.CXCR4 0.71 ± 0.002, n = 3, 60 min p.i.). [ 111 In]In-DOTAGA-VUN400-C demonstrated nearly identical plasma stability (41.08 ± 5.45%, n = 4) but showed high and specific uptake in the CXCR4-expressing xenografted tumor (SUV U87.CD4.CXCR4 3.75 ± 1.08 vs SUV U87.CD4 = 0.64 ± 0.19, n = 5, 60 min p.i.), which could be blocked by coinjection of AMD3100 (5 mg/kg) (SUV U87.CD4.CXCR4 0.55 ± 0.32 vs SUV U87.CD4 = 0.39 ± 0.07, n = 2, 60 min p.i.). In conclusion, all six sdAbs exhibited high in vitro affinity against hCXCR4. Among these, [ 111 In]In-DOTAGA-VUN400-C showed high CXCR4-specific tumor uptake and favorable pharmacokinetic properties, indicating VUN400-C’s potential as a promising vector for future CXCR4 PET imaging applications with fluorine-18.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium.
- QVQ Holding B.V., Yalelaan 1, Utrecht 3584 CL, The Netherlands.
- Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam 1081 HV, The…
- KU Leuven, Department of Microbiology, Immunology and Transplantation Rega Institute for Medical Research,Molecular Structural and Translational Virology Research Group, Leuven B-3000, Belgium.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven 3000, Belgium.
ORCID-Profile: Tom Van Loy, Christopher Cawthorne, Guy Bormans, Frederik Cleeren
Förderung
- KU Leuven
- H2020 Marie Sklodowska-Curie Actions
- Fonds Wetenschappelijk Onderzoek
- Stichting Tegen Kanker
Zitieren
APA
Spahn, M. A., Anbuhl, S. M., Luyten, K., Loy, T. V., Pronker, M. F., Cawthorne, C., Deroose, C. M., Schols, D., Heukers, R., Bormans, G., & Cleeren, F. (2025). Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00024
Vancouver
Spahn MA, Anbuhl SM, Luyten K, Loy TV, Pronker MF, Cawthorne C, et al. Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00024
BibTeX
@article{Spahn2025,
author = {Spahn, Muriel Aline and Anbuhl, Stephanie Mareike and Luyten, Kaat and Loy, Tom Van and Pronker, Matti F and Cawthorne, Christopher and Deroose, Christophe M and Schols, Dominique and Heukers, Raimond and Bormans, Guy and Cleeren, Frederik},
title = {Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00024}
}
EUVIMED